Neurodiversity, ADHD, Autism, and AuDHD
Flipping the Script on ADHD Care: The Case for Non-Stimulants as a First-Line Treatment (Additudemag)
Summary: Two prominent ADHD researchers argue that the decades-long stimulant-first prescribing paradigm may not serve all patients, citing network meta-analyses showing only a modest statistical edge for stimulants and trial data revealing that nearly half of children respond excellently to atomoxetine. They propose parallel first-line pathways for stimulants and non-stimulants, driven by practical burdens—shortages, regulatory friction, diversion—and are testing this approach in a PCORI-funded clinical trial.
Why it matters: This challenges the foundational prescribing hierarchy in ADHD care, potentially reshaping clinical guidelines, insurance coverage, and patient access—especially for the 10% currently receiving non-stimulants and the millions navigating stimulant shortages and controlled-substance restrictions.
Context: Current AAP and AACAP guidelines reserve non-stimulants for stimulant failures or contraindications; real-world data show 90% of ADHD prescriptions are stimulants. The authors’ proposed trial directly tests whether a non-stimulant-first strategy yields comparable outcomes with fewer systemic burdens.
"From that data, we calculated that a doctor must prescribe stimulants instead of non-stimulants to eight patients just to see one additional patient do better than they would have if they had taken a non-stimulant." — ADDITUDEMAG
Commentary: The NNT of 8 is a powerful, concrete statistic that undercuts the ‘undisputed heavyweight’ framing—though the authors wisely avoid overclaiming, acknowledging non-stimulants’ slower onset. The real shift here is regulatory: if guidelines move to parallel pathways, expect pressure on DEA scheduling, telemedicine rules, and prior authorization policies. Watch for the PCORI trial results; they could be the evidence base that forces guideline committees to revisit first-line defaults.
Date: July 27, 2026 05:54 AM ET
URL: https://www.additudemag.com/stimulant-vs-non-stimulant-adhd-meds/
AI Sentiment Score: Negative (75%)
AI Credibility Score: 10.0/10 — High
Scores and text generated by AI analysis of the source article indicated.How the neurodiversity movement has left some autism families behind (San)
Summary: The neurodiversity movement has reshaped autism from a medical disability into an identity, but parents of children with profound autism argue this shift has diverted research, funding, and policy attention away from those with the highest support needs. Families report being turned away from programs, facing guardianship opposition, and struggling to establish residential communities due to state regulations. The debate extends to ABA therapy, with advocates opposing it while many parents rely on it as the only available intervention. As the movement gains influence, the gap between the ‘slightly eccentric verbal autistic adults’ and those requiring lifelong round-the-clock care widens, leaving the latter with an uncertain future.
Why it matters: This article exposes a critical fault line in autism policy: the neurodiversity movement’s success in reshaping public perception may be inadvertently marginalizing the most vulnerable autistic individuals, affecting how billions in Medicaid funds and research dollars are allocated.
Context: The piece is part of a five-part series on autism, following coverage of expanding diagnostic criteria and rising prevalence. It highlights a growing tension between self-advocates and parents of profound autism, a divide that has intensified as the definition of autism has broadened.
"Parents or support teams for autistic people with higher support needs are worried about their kids disappearing in terms of getting resources, in terms of getting public attention, and kind of being replaced by this image of like the slightly eccentric verbal autistic adults who can function relatively independently,” Price said. “I think when they’re worried about that, they’re completely right." — SAN
Commentary: The article crystallizes a policy paradox: the neurodiversity movement’s advocacy for inclusion and self-determination has inadvertently deprioritized those who cannot self-advocate, creating a resource vacuum. The $2.2 billion Medicaid ABA spending surge, driven by for-profit clinics, raises questions about whether the system is serving the highest-need populations or merely the most tractable ones. The guardianship and residential housing disputes are not just philosophical—they have concrete legal and financial consequences for families like Amy Lutz’s, who face state restrictions that force them into inadequate care models. As the movement’s influence grows, the risk is that ‘profound autism’ becomes a policy afterthought, with the most vulnerable left to an uncertain future.
Date: July 31, 2026 06:30 AM ET
URL: https://san.com/cc/how-the-neurodiversity-movement-has-left-some-autism-families-behind
AI Sentiment Score: Positive (50%)
AI Credibility Score: 10.0/10 — High
Scores and text generated by AI analysis of the source article indicated.Studies Highlight Rapid Expansion of ADHD Drug Prescribing (Madinamerica)
Summary: Three new studies document a rapid expansion of ADHD drug prescribing across the US, Canada, and Australia. US youth psychiatric drug use rose from 5.3% to 8.3% between 2001–2004 and 2017–2020, driven largely by stimulants, with young adults seeing a 28-fold increase in stimulant use. In Ontario, new stimulant prescriptions surged 175% during COVID, with women and young adults disproportionately affected. In Australia, ADHD drug prescriptions nearly tripled after telepsychiatry expansion, particularly in remote video consultations. All three studies note limitations including lack of diagnostic data and reliance on administrative records.
Why it matters: For readers tracking neurodiversity and ADHD, these findings signal a structural shift in how ADHD is diagnosed and treated—via telepsychiatry, with new prescriber types, and with demographic skews—raising questions about overdiagnosis, access, and the long-term effects of expanded stimulant use.
Context: The studies span three continents and different health systems, yet converge on a common pattern: ADHD drug prescribing is expanding faster than other psychiatric drug classes, often through new channels like telepsychiatry and nurse practitioners, and disproportionately among women and young adults.
"Prescription rates for ADHD drugs increased nearly threefold, from 4.3% of psychiatric consultations before the expansion of telepsychaitry to 11.8% of consultations after. This increase was especially significant in remote video psychiatric consultations, where 1.8% of pre-expansion remote video consultations were linked to stimulant prescriptions compared to 23.4% after the expansion." — MADINAMERICA
Commentary: The Australian telepsychiatry data is the most striking: a 13-fold increase in stimulant prescribing via remote video consultations suggests that access expansion, not just clinical need, is driving the surge. The Ontario finding that nurses and nurse practitioners increased their stimulant prescribing from 1.7% to 9.6% of new scripts points to a parallel broadening of prescriber authority. For the neurodiversity community, this raises a tension: improved access for underserved groups versus the risk of pathologizing normal variation. The lack of diagnostic data in all three studies is a critical gap—prescription rates are not the same as prevalence, and the field needs better longitudinal outcomes research to assess whether this expansion is helping or harming.
Date: July 31, 2026 06:00 AM ET
URL: https://madinamerica.com/2026/07/studies-highlight-rapid-expansion-of-adhd-drug-prescribing
AI Sentiment Score: Negative (50%)
AI Credibility Score: 10.0/10 — High
Scores and text generated by AI analysis of the source article indicated.Autism and Eating Disorders: 3 Common Overlooked Challenges (Autisticadvocacy)
Summary: Sam Sharpe, PhD, writing for the Autistic Self Advocacy Network via the FEDUP Collective, identifies three overlooked challenges autistic people face with eating: executive-function demands around feeding, the diagnostic and treatment ambiguities of ARFID, and sensory-driven body image distress. The piece argues that standard eating disorder frameworks mischaracterize these experiences, leading to inadequate care and pathologization. It calls for neuroaffirming, individualized approaches, including occupational therapy, over normative eating interventions.
Why it matters: For clinicians, researchers, and autistic adults, this reframes eating difficulties as neurodivergent-specific phenomena rather than deficits, with direct implications for diagnostic accuracy, treatment design, and the growing ARFID literature.
Context: ARFID is already recognized as more prevalent in autistic populations, but this piece highlights how neuronormative assumptions in eating disorder care—especially around body image and executive function—remain unaddressed in mainstream treatment protocols.
"In most eating disorder treatment programs, body image interventions focus on addressing aesthetic aspects of body image and body image distress. These types of interventions are typically not adequate to understand and provide support for body image distress related to sensory input, which can mean that individuals impacted by these types of body distress may feel misunderstood and unsupported." — AUTISTICADVOCACY
Commentary: The sensory-body-image argument is the sharpest contribution here, as it moves beyond the aesthetic focus that dominates ED research and points to interoceptive and proprioceptive inputs as understudied drivers. The practical implication is that occupational therapy should be a standard referral for autistic patients with eating concerns, not an afterthought. For researchers, this suggests a need to operationalize sensory body image in assessment tools, which could reduce misdiagnosis of ARFID as anorexia. The piece also implicitly critiques the field’s outcome metrics: treatment success should be measured by nutritional adequacy and quality of life, not conformity to neurotypical eating patterns.
Date: July 31, 2026 05:00 PM ET
URL: https://autisticadvocacy.org/2026/07/autism-and-eating-disorders-3-common-overlooked-challenges/
AI Sentiment Score: Negative (60%)
AI Credibility Score: 10.0/10 — High
Scores and text generated by AI analysis of the source article indicated.Post ID: c1474e6e